Healthcare League Tables?
Anyone have access to the healthcare league tables? Looked all over WSO and online and it seems p difficult to find, any help is appreciated.
Trending Content - Investment Banking Forum
| +148 | ONLY THESE BANKS OR YOU STRUCK OUT | 38 | 13h |
| +111 | IB Energy Drink Tier List / Ranking | 73 | 1d |
| +61 | Firm Thinks I'm Lying About Offer | 19 | 16h |
| +53 | Indiana University Fraternity Pipelines | 32 | 13h |
| +51 | Feedback for internship first desk at IBD BB - personal fit, "don't be too confident" | 29 | 2d |
| +39 | Stay at Weak Dealflow Team or Lateral? | 12 | 21h |
| +36 | Rogo AI | 14 | 11h |
| +34 | Elite Boutique interview questions | 8 | 1d |
| +30 | Suspended for a Year | 11 | 14h |
| +23 | 1st Half 2026 (1H26) RX IB & RX Co. Rankings | 14 | 1d |
Career Resources
It’s something like:
Citi and Jefferies might be switched but that’s the general order, and it’s pretty similar for US/Global and M&A/all products
You’re forgetting the folks at the top - Evercore, Centerview, and a bit of PJT and Moelis
Also JPM is way ahead of GS in HC
Way ahead is a stretch, just ran a FactSet screen and GS is actually ahead when it comes to announced M&A deals for 2021. JPM does more financings which boosts up their total deal count and deal amount. JPM does fantastic, definitely the perennial favorite in the space with their HC Conference and large balance sheet. That said, GS is def no slouch and MS and BoFA aren't far behind.
To respond to your second comment about Evercore, CVP, etc...Centerview and Evercore is indeed up there, especially on the M&A standpoint. However, Moelis and PJT are still a ways off. In fact, Jefferies and Guggenheim are ahead of those two respectively. Moelis doesn't announce deal size for many of their deals given they're private and also aren't particularly active in Pharma. PJT does sporadic large deals but doesn't have consistency.
Stop speaking out of your ass, especially if you are going to hit me with ms. 2021 Americas fees by all products goes:
So Citi was lower and throw in CVP up there. If you run it by M&A volume, GS is still ahead of JPM by a sizable amount (~$60bn).
Do you have breakdown of fees for each?
Repellat pariatur sed temporibus vel consequatur eius repellendus. Est enim qui nemo quisquam vitae accusantium autem velit. Rerum quibusdam sunt nihil aut esse.
Eos praesentium rem et repellat. Quod accusamus quia reiciendis voluptatibus cupiditate libero nihil. Dolorum ducimus hic at ut tenetur.
Aut non modi ducimus debitis amet asperiores. Aliquid sequi et enim ex sed. Omnis sed voluptates magnam officia id aut. Veniam aut quia repellendus minus totam voluptatem. Non et consectetur est asperiores quia qui omnis natus.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...